Cargando…
MEDB-26. Outcomes of children with standard-risk and high-risk medulloblastoma treated with pre-irradiation chemotherapy and risk-adapted craniospinal irradiation: a report on patients from the Polish Pediatric Neuro-oncology Group
BACKGROUND: The last two decades have witnessed several efforts to minimize the adverse sequelae of craniospinal irradiation (CSI), a standard of care treatment modality in medulloblastoma. This has been accomplished by adding chemotherapy to the treatment backbone. The use of pre-irradiation chemot...
Autores principales: | Perek-Polnik, Marta, Cochrane, Anne, Chojnacka, M, Drogosiewicz, M, Filipek, I, Swieszkowska, E, Tarasinska, M, Kowalczyk, P, Abdelbaki, Mohamed S, Dembowska-Bagińska, Bożenna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165299/ http://dx.doi.org/10.1093/neuonc/noac079.400 |
Ejemplares similares
-
Risk-Adapted Treatment Strategies with Pre-Irradiation Chemotherapy in Pediatric Medulloblastoma: Outcomes from the Polish Pediatric Neuro-Oncology Group
por: Perek-Polnik, Marta, et al.
Publicado: (2023) -
MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?
por: Erker, Craig, et al.
Publicado: (2022) -
MEDB-54. Standard Risk Medulloblastoma treated solely with surgery and chemo-radiation
por: Cantor, Evan, et al.
Publicado: (2022) -
MEDB-58. Risk factors and risk prediction models for medulloblastoma recurrence
por: Li, Juan, et al.
Publicado: (2022) -
MEDB-17. Re-irradiation for recurrent medulloblastoma in a matched cohort: Advantageous especially in patients without resection
por: Adolph, Jonas E, et al.
Publicado: (2022)